Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominant IBS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs TC 6499 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Targacept
- 25 Jun 2014 Primary endpoint has not been met according to a Targacept Media Release. (Change from baseline in global IBS symptom relief score)
- 25 Jun 2014 Results published in a Targacept Media Release.
- 04 Jan 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.